<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195677">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543894</url>
  </required_header>
  <id_info>
    <org_study_id>SRP-HB-MER-2005/1</org_study_id>
    <nct_id>NCT00543894</nct_id>
  </id_info>
  <brief_title>Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients</brief_title>
  <acronym>ANTHICUS</acronym>
  <official_title>Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A Prospective, Observational, Multicenter Study (ANTHICUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A prospective,
      observational, multicenter study (ANTHICUS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <secondary_outcome>
    <measure>the frequency of appropriate antibiotic therapy (defined as the use of antibiotic(s) with &quot;in vitro&quot; efficacy against the identified pathogens responsible for the infection)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of &quot;the strategy of de-escalation&quot; according to the culture results</measure>
  </secondary_outcome>
  <enrollment type="Actual">500</enrollment>
  <condition>Infection in ICU</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hospital-acquired infections and hospitalised in the ICU at one moment
             of their hospital stay

          -  Hospital-acquired infections accounting for eligibility are:

               -  nosocomial pneumonia (including ventilator-associated pneumonia)

               -  bacteremia

               -  intra-abdominal infections

               -  urosepsis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Pr Vogelaers</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Gents</affiliation>
  </overall_official>
  <verification_date>June 2007</verification_date>
  <lastchanged_date>August 11, 2008</lastchanged_date>
  <firstreceived_date>October 11, 2007</firstreceived_date>
  <keyword>Antibiotic, ICU, hospital acquired infection.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
